Ovarian follicular and corpus luteum changes, progesterone concentrations, estrus and ovulation following estradiol benzoate/progesterone based treatment protocol in cross-bred cows.
The objectives of the present study were to investigate the effects of the stage of the estrous cycle at the start of an estradiol benzoate (EB) and progesterone (P) based treatment protocol on new follicular wave emergence, subsequent estrus and ovulation. The experiment was conducted using a crossover design with each cow (five cross-bred cows) being assigned to one of three groups at 3-month intervals within a 1-year period. Estrous cycle stage in individual cows was initially synchronized with prostaglandin F(2)alpha. After detection of estrus, each cow was injected intramuscularly (i.m.) with 2 mg EB and 200 mg P (EB/P) on day 5, 12 or 17 of the estrous cycle (estrus=day 0), followed by 1 mg EB i.m. 12 days after the EB/P treatment. Ovarian ultrasonographic examinations showed that the emergence of a new follicular wave occurred after EB/P treatment in all groups and the mean interval from EB/P treatment to wave emergence did not differ among the groups (3.2-3.8 days). All cows in each group exhibited behavioral estrus and ovulated the newly formed dominant follicle. However, cows in the day-17 group exhibited estrus 1-3 days before the second EB injection. The concentrations of progesterone showed faster reduction, during the treatment period, in the day-12 and -17 groups compared to the day-5 group. These results indicate that the EB/P treatment induces an emergence of a new follicular wave, irrespective of the estrous cycle stage at the start of treatment, but the effect of EB/P protocol on estrous/ovulation synchronization is influenced by the stage of the estrous cycle.
Taniguchi
M
M
Laboratory of Animal Reproduction, The United Graduate School of Veterinary Science, Yamaguchi University, Yamaguchi, Japan.
Ikeda
A
A
Arikawa
E
E
Shimizu
R
R
Seki
M
M
Karaki
M
M
Rajamahendran
R
R
Otoi
T
T
D000818:Animals; D002417:Cattle / Q000502:physiology*; D003338:Corpus Luteum / Q000187:drug effects*; D018592:Cross-Over Studies; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D030762:Estrous Cycle / Q000187:drug effects; D004971:Estrus / Q000187:drug effects*; D004973:Estrus Synchronization / Q000187:drug effects; D005260:Female; D005300:Fertility Agents, Female / Q000494:pharmacology; D006080:Ovarian Follicle / Q000187:drug effects*; D010060:Ovulation / Q000187:drug effects*; D011374:Progesterone / Q000097:blood* / Q000494:pharmacology
D005300:Fertility Agents, Female; C074283:estradiol 3-benzoate; D011374:Progesterone; D004958:Estradiol